PublishedMarch 17, 2026 Category Partner News Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
PublishedMarch 10, 2026 Category Partner News Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
PublishedMarch 10, 2026 Categories eFlow Integrated PARI Publications A Novel HF User Characteristics Assessment Approach for a New Platform-Based, Breath-Triggered Nebulizer in Inhalation Therapy
PublishedMarch 10, 2026 Category PARI Publications From Continuity to Competitive Edge – How Long-Term Collaboration Drives HF Program Success
PublishedMarch 5, 2026 Category Partner News Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
